Cargando…
Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice
INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464642/ https://www.ncbi.nlm.nih.gov/pubmed/36105617 http://dx.doi.org/10.2147/IJN.S359114 |
_version_ | 1784787628604784640 |
---|---|
author | Saad, Muhammed A Eissa, Noha M Ahmed, Mohammed A ElMeshad, Aliaa N Laible, Götz Attia, Ahmed S Al-Ghobashy, Medhat A Abdelsalam, Rania M Al-Shorbagy, Muhammad Y |
author_facet | Saad, Muhammed A Eissa, Noha M Ahmed, Mohammed A ElMeshad, Aliaa N Laible, Götz Attia, Ahmed S Al-Ghobashy, Medhat A Abdelsalam, Rania M Al-Shorbagy, Muhammad Y |
author_sort | Saad, Muhammed A |
collection | PubMed |
description | INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison with other treatment groups to determine its potential neuro-protective effects on C57BL/6 mice after inducing experimental autoimmune encephalomyelitis (EAE). METHODS: EAE was induced in the corresponding mice by injecting 100 μL of an emulsion containing complete Freund’s adjuvant (CFA) and myelin oligodendrocyte glycoprotein (MOG). The subjects were weighed, scored and subjected to behavioural tests. After reaching a clinical score of 3, various treatments were given to corresponding EAE-induced and non-induced groups including rhMBP, RTX, empty nanoparticle prepared by poly (lactide-co-glycolide) (PLGA) or the prepared nanoformulation (Nano-rhMBP-RTX). At the end of the study, biochemical parameters were also determined as interferon-γ (IFN-γ), myeloperoxidase (MPO), interleukin-10 (IL-10), interleukin-4 (IL-4), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-kB), brain derived neurotrophic factor (BDNF), 2’, 3’ cyclic nucleotide 3’ phosphodiesterase (CNP) and transforming growth factor beta (TGF-β) along with some histopathological analyses. RESULTS: The results of the Nano-rhMBP-RTX group showed promising outcomes in terms of reducing the clinical scores, improving the behavioural responses associated with improved histopathological findings. Elevation in the levels of IL-4, CNP and TGF-β was also noticed along with marked decline in the levels of NF-kB and TNF-α. CONCLUSION: Nano-rhMBP-RTX treated group ameliorated the adverse effects induced in the EAE model. The effectiveness of this formulation was demonstrated by the normalization of EAE-induced behavioral changes and aberrant levels of specific biochemical markers as well as reduced damage of hippocampal tissues and retaining higher levels of myelination. |
format | Online Article Text |
id | pubmed-9464642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94646422022-09-13 Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice Saad, Muhammed A Eissa, Noha M Ahmed, Mohammed A ElMeshad, Aliaa N Laible, Götz Attia, Ahmed S Al-Ghobashy, Medhat A Abdelsalam, Rania M Al-Shorbagy, Muhammad Y Int J Nanomedicine Original Research INTRODUCTION: Rituximab (RTX) and recombinant human myelin basic protein (rhMBP) were proven to be effective in ameliorating the symptoms of multiple sclerosis (MS). In this study, a nanoformulation containing rhMBP with RTX on its surface (Nano-rhMBP-RTX) was prepared and investigated in comparison with other treatment groups to determine its potential neuro-protective effects on C57BL/6 mice after inducing experimental autoimmune encephalomyelitis (EAE). METHODS: EAE was induced in the corresponding mice by injecting 100 μL of an emulsion containing complete Freund’s adjuvant (CFA) and myelin oligodendrocyte glycoprotein (MOG). The subjects were weighed, scored and subjected to behavioural tests. After reaching a clinical score of 3, various treatments were given to corresponding EAE-induced and non-induced groups including rhMBP, RTX, empty nanoparticle prepared by poly (lactide-co-glycolide) (PLGA) or the prepared nanoformulation (Nano-rhMBP-RTX). At the end of the study, biochemical parameters were also determined as interferon-γ (IFN-γ), myeloperoxidase (MPO), interleukin-10 (IL-10), interleukin-4 (IL-4), tumor necrosis factor alpha (TNF-α), nuclear factor kappa B (NF-kB), brain derived neurotrophic factor (BDNF), 2’, 3’ cyclic nucleotide 3’ phosphodiesterase (CNP) and transforming growth factor beta (TGF-β) along with some histopathological analyses. RESULTS: The results of the Nano-rhMBP-RTX group showed promising outcomes in terms of reducing the clinical scores, improving the behavioural responses associated with improved histopathological findings. Elevation in the levels of IL-4, CNP and TGF-β was also noticed along with marked decline in the levels of NF-kB and TNF-α. CONCLUSION: Nano-rhMBP-RTX treated group ameliorated the adverse effects induced in the EAE model. The effectiveness of this formulation was demonstrated by the normalization of EAE-induced behavioral changes and aberrant levels of specific biochemical markers as well as reduced damage of hippocampal tissues and retaining higher levels of myelination. Dove 2022-09-07 /pmc/articles/PMC9464642/ /pubmed/36105617 http://dx.doi.org/10.2147/IJN.S359114 Text en © 2022 Saad et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Saad, Muhammed A Eissa, Noha M Ahmed, Mohammed A ElMeshad, Aliaa N Laible, Götz Attia, Ahmed S Al-Ghobashy, Medhat A Abdelsalam, Rania M Al-Shorbagy, Muhammad Y Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title | Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title_full | Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title_fullStr | Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title_full_unstemmed | Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title_short | Nanoformulated Recombinant Human Myelin Basic Protein and Rituximab Modulate Neuronal Perturbations in Experimental Autoimmune Encephalomyelitis in Mice |
title_sort | nanoformulated recombinant human myelin basic protein and rituximab modulate neuronal perturbations in experimental autoimmune encephalomyelitis in mice |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464642/ https://www.ncbi.nlm.nih.gov/pubmed/36105617 http://dx.doi.org/10.2147/IJN.S359114 |
work_keys_str_mv | AT saadmuhammeda nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT eissanoham nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT ahmedmohammeda nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT elmeshadaliaan nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT laiblegotz nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT attiaahmeds nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT alghobashymedhata nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT abdelsalamraniam nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice AT alshorbagymuhammady nanoformulatedrecombinanthumanmyelinbasicproteinandrituximabmodulateneuronalperturbationsinexperimentalautoimmuneencephalomyelitisinmice |